상피 성장인자 수용체 변이 양성 비소세포폐암(EGFR-NSCLC) - 시장 인사이트, 역학, 시장 예측(2036년)

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Insights and Trends

• According to DelveInsight's analysis, EGFR NSCLC market size was found to be ~USD 6,600 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• EGFR-mutated NSCLC is more prevalent in Asian counties such as Japan, with mutation rates estimated at 45%, compared to 15% in Western countries. Majorly due to genetic predisposition, lower smoking rates among Asian patients, and distinct environmental factors that contribute to a higher likelihood of oncogenic driver mutations.
• Males face a higher lifetime risk of developing lung cancer and experience greater mortality compared to females. This disparity is partly attributed to lifestyle factors, as men are more likely to engage in cigarette smoking, alcohol consumption, high-calorie diets, and drug use, all of which elevate lung cancer risk.
• NSCLC is increasingly becoming a biomarker-driven market, and EGFR is one of the most profitable biomarker segments, led by blockbuster therapies such as osimertinib (TAGRISSO), which now generates nearly USD 6 billion annually. The prevalence of patients with this resistance mutation has increased since TAGRISSO was authorized for use in the first line. The post-TAGRISSO setting is one of the highest areas of unmet need.
• The ADC space in EGFR NSCLC awaits more launches down the road, with several compounds under development in pivotal studies. The ADC space in EGFR NSCLC awaits more launches down the road, with several compounds under development in pivotal studies. After the approval of Dato-Dxd, leading pharma players drive ADC innovation with agents such as izalontamab brengitecan (BMS), telisotuzumab adizutecan (AbbVie), and sacituzumab tirumotecan (Merck).
• Convergence of TKIs, ADCs, bispecifics, CDAC, and gene-therapy combinations signals a densely crowded and competitive future, where differentiation by efficacy, resistance coverage, administration route, and combination potential will define market winners.
• From last few years, exon 20 insertions EGFR mutations have received the most attention and this space has become competitive. In EGFR NSCLC, uncommon/atypical EGFR mutations (G719X, S768I, as well as PACC mutations), represent another frontier in this segment.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Market Size and Forecast

• 2025 EGFR NSCLC Market Size: ~USD 6,600 million
• 2036 Projected EGFR NSCLC Market Size: ~USD 14,200 million
• EGFR NSCLC Growth Rate (2026-2036): 7.3% CAGR

DelveInsight's 'Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the EGFR NSCLC, historical and forecasted epidemiology, as well as the EGFR NSCLC market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates, EGFR NSCLC patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in EGFR NSCLC and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Understanding and Treatment Algorithm

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Overview and Diagnosis

EGFR is a protein in cells that helps them grow. A mutation in the gene for EGFR can make it grow too much, which can cause cancer. There are different types of EGFR mutations, including deletions or insertions and point mutations. In test results, individuals may be identified as having an EGFR 19 deletion or an EGFR L858R point mutation, which are the most common types of EGFR mutations. These mutations are typically treated the same way. Amongst the EGFR mutations that are tested for in lung cancer, a few rare types are treated differently than the more common EGFR mutations. The major example of this in lung cancer is EGFR exon 20 insertions. This is a type of EGFR mutation that does not respond to the typical treatment for EGFR-positive lung cancer, which are called tyrosine kinase inhibitors, or TKIs.

In general, there are two ways to detect EGFR mutations. The best way is through comprehensive next-generation sequencing (NGS). This type of testing places tissue from a patient's tumor (gathered from a biopsy) in a machine that looks for a large number of possible biomarkers at one time. There may be some situations where a patient cannot undergo the biopsy needed to perform NGS, so liquid biopsy is recommended. A liquid biopsy can look for certain biomarkers in a patient's blood.

Current Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Treatment Landscape

Treatment of EGFR-mutated NSCLC mainly involves targeted therapies called EGFR tyrosine kinase inhibitors (TKIs), which block the abnormal EGFR signaling that drives tumor growth. Commonly used TKIs include first-, second-, and third-generation agents such as osimertinib, erlotinib, and afatinib. For patients with specific resistant mutations like EGFR exon 20 insertions, alternative targeted therapies or newer agents may be used instead of standard TKIs. In some cases, chemotherapy, immunotherapy, or combination therapies may also be considered depending on the mutation type and disease stage.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Unmet Needs

The section "unmet needs of Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC)" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Problem of Resistance Development

2. CNS Metastases and Limited Brain Penetration

3. Limited Access and Affordability

4. Therapy Gaps after Targeted Therapy Progression, and others.....

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Epidemiology

Key Findings from EGFR NSCLC Epidemiological Analysis and Forecast

• According to DelveInsight's estimates, the total number of incident cases of NSCLC in the 7MM was nearly 540,000 cases in 2025 and is projected to increase during the forecasted period.
• The total number of incident cases of NSCLC in the United States was nearly 202,900 in 2025.
• In 2025, adenocarcinoma (~116,000 cases) accounted for the largest share of incident NSCLC cases in the United States, followed by squamous cell carcinoma, while large cell carcinoma comprised the smallest proportion.
• The total number of cases of EGFR NSCLC in the United States was estimated to be nearly 30,400 in 2025.
• NSCLC shows a slight male predominance and is most common in individuals aged =65 years. However, cases among people younger than 65 are increasing, likely due to changing smoking patterns, environmental and occupational exposures, air pollution, and improved early diagnostic detection.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Drug Analysis & Competitive Landscape

The EGFR NSCLC drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I/II-II clinical trials. It covers mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, strategic partnerships upcoming Key catalyst for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the EGFR NSCLC treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the EGFR NSCLC therapeutics market.

Approved Therapies for EGFR NSCLC

Osimertinib (TAGRISSO): AstraZeneca

Osimertinib is a prescription medicine for adults with NSCLC with abnormal EGFR genes. It is used to prevent recurrence after surgery, as a first-line treatment for metastatic NSCLC, or when previous EGFR TKI treatments have failed. Osimertinib is a kinase inhibitor that targets mutant EGFR forms (T790M, L858R, exon 19 deletions) at lower concentrations than wild-type EGFR. In November 2015, it was initially approved 80mg once-daily tablets for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC. In February 2024, the FDA approved osimertinib with platinum-based chemotherapy for patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Pipeline Analysis

Zipalertinib: Cullinan Oncology/Taiho Pharmaceutical

Zipalertinib (CLN-081/TAS6417) is a novel, orally bioavailable, irreversible EGFR inhibitor that, based on preclinical models, selectively and potently targets cells expressing EGFRex20ins mutations while relatively sparing cells expressing wild-type EGFR to avoid the toxicities associated with inhibition of wild-type EGFR. This was rationally designed with a distinct chemical scaffold to be highly selective for mutant vs. wild-type EGFR and to avoid inhibiting the closely related receptor human epidermal growth factor receptor 2 (HER2). Zipalertinib demonstrates the potential to become a new standard of care to treat non-small cell lung cancer harboring EGFRex20ins mutations.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Key Players, Market Leaders and Emerging Companies

• Cullinan Oncology
• Taiho Pharmaceuticals
• ArriVent BioPharma
• Akeso Biopharma
• Summit Therapeutics
• Pfizer
• Daiichi Sankyo
• AstraZeneca
• Merck
• Kelun-Biotech
• CSPC Pharmaceutical
• Shanghai JMT-Bio
• Bristol-Myers Squibb, and others

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Drug Updates

• In January 2026, the US FDA accepted for filing Summit's Biologics License Application (BLA) for the HARMONi Phase III trial and assigned a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026.
• In November 2025, a New Drug Application (NDA) was submitted for zipalertinib for the treatment of EGFR exon 20-mutant NSCLC, with completion and priority review planned for Q1 2026, based on data from the REZILIENT1 Phase I/II study.
• Silvertinib is being evaluated for 1L NSCLC, with Phase II DOR/PFS data expected in Q2 2026 and subsequent FDA feedback. Final Phase II data in 2L/3L NSCLC are also expected in Q2 2026, and the drug has received FDA Fast Track Designation (FTD) for C797S+ patients while partnering options for pivotal development are being explored.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Market Outlook

Treatment of EGFR-mutant NSCLC has improved with targeted EGFR TKIs over the past two decades. First-generation TKIs (erlotinib, gefitinib), second-generation TKIs (afatinib, dacomitinib), and the third-generation TKI (osimertinib) have progressively improved response and survival compared with chemotherapy. Osimertinib is also effective against the T790M resistance mutation; however, drug resistance still develops and optimal treatment after TKI failure remains challenging.

Osimertinib remains the global standard of care for EGFR-mutant NSCLC, supported by strong overall survival (OS) and progression-free survival (PFS) data and broad approvals across disease stages. Amivantamab is emerging as a key competitor, expanding beyond EGFR exon 20 mutations through combination regimens with lazertinib and chemotherapy. The landscape is becoming more competitive with new entrants such as Datopotamab deruxtecan, Sunvozertinib, and Aumolertinib. Real-world data from the 7MM show that EGFR TKIs dominate treatment, with osimertinib widely used as first-line therapy, while chemotherapy and immunotherapy remain options in later lines or for rare mutations (e.g., exon 20 insertions).

EGFR exon 20 insertion NSCLC is difficult to treat with standard TKIs. Amivantamab was the main approved therapy after mobocertinib was withdrawn. In 2025, Sunvozertinib was approved, increasing competition, while TKIs like Furmonertinib and Zipalertinib are in development. Emerging ADCs and next-generation therapies are further intensifying competition in the EGFR NSCLC market.

Overall, the launch of first-in-class therapies, improved genetic testing, and rising disease awareness are expected to drive steady growth in the 7MM EGFR NSCLC market from 2022-2036, with strong commercial implications for both marketed products and emerging pipelines.

• Among the 7MM, the US accounted for the largest market size of EGFR NSCLC. i.e., USD ~3,800 million in 2025.
• In 2036, among all the therapies for EGFR NSCLC, the highest revenue is estimated to be generated by amivantamab (RYBREVANT) +- lazertinib (LAZCLUZE) followed by osimertinib (TAGRISSO), in the US.
• The entry of late-stage candidates such as zipalertinib, furmonertinib is expected to intensify competition in the EGFR NSCLC treatment landscape during the latter forecast period.

Drug Class/Insights into Leading Emerging and Marketed Therapies in EGFR NSCLC (2022-2036 Forecast)

The EGFR NSCLC market comprises monoclonal/bispecific antibody, ADC, and small molecules, each targeting different aspects of EGFR NSCLC.

• Small molecules: Small-molecule therapies in development for EGFR-mutant NSCLC include zipalertinib (CLN-081) by Cullinan Oncology/Taiho Pharma, firmonertinib by ArriVent BioPharma, and LP-300 by Lantern Pharma.
• ADCs: Key ADCs in the pipeline include PF-08046054 (Pfizer), patritumab deruxtecan (Daiichi Sankyo/AstraZeneca), sacituzumab tirumotecan (MK-2870) (Merck/Kelun-Biotech), SYS6010 (CSPC Pharmaceutical), izalontamab brengitecan (BMS-986507) (Bristol-Myers Squibb), and telisotuzumab adizutecan (ABB-400) (AbbVie).

Small molecules and ADCs defines the core innovation landscape, with monoclonal and bispecific antibodies currently commercially validated and small molecules driving pipeline growth.

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the EGFR NSCLC drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

The uptake of therapies in EGFR NSCLC is expected to vary based on clinical positioning, mechanism of action, and stage of development. Adoption of amivantamab (RYBREVANT) + chemotherapy and amivantamab (RYBREVANT) + lazertinib (LAZCLUZE) in EGFR NSCLC is expected to occur at a moderate uptake rate, supported by their targeted approach, favorable clinical data, and increasing integration into earlier lines of therapy.

The adoption of emerging therapies in EGFR-mutant NSCLC is expected to vary based on clinical maturity, combination strategies, and differentiation from existing standards of care. Furmonertinib/firmonertinib may achieve relatively faster uptake due to encouraging clinical data and potential positioning in targeted therapy settings. In contrast, pamvatamig (MCLA-129) +- osimertinib and telisotuzumab adizutecan (Temab-A) + TAGRISSO are likely to experience gradual uptake, reflecting their earlier clinical positioning and the need for stronger comparative evidence against established EGFR TKIs.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved therapies in Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC)

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) Therapies Price Scenario & Trends

Pricing and analogue assessment of EGFR NSCLC therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most approproiate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

• Pricing of EGFR NSCLC Approved Drugs

In the first-line setting, treatment costs vary significantly, with platinum-based chemotherapy estimated at USD 8,747, first- and second-generation TKIs at USD 27,943, and osimertinib reaching approximately USD 212,580, reflecting the higher cost associated with targeted therapies.

Industry Experts and Physician Views for Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC)

To keep up with EGFR NSCLC market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on the EGFR NSCLC emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in EGFR NSCLC, including MD, Ph.D, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at country level. Centers such as the Ohio State University, Norris Comprehensive Cancer Center, and University of Southern California, etc. were contacted. Their opinion helps understand and validate current and emerging EGFR NSCLC therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in EGFR NSCLC.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of EGFR NSCLC, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC), explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM Epidermal Growth Factor Receptor (EGFR) Non-small Cell Lung Cancer (NSCLC) market.

Report Insights

• EGFR NSCLC Patient Population Forecast
• EGFR NSCLC Therapeutics Market Size
• EGFR NSCLC Pipeline Analysis
• EGFR NSCLC Market Size and Trends
• EGFR NSCLC Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-enabled Market Research Report
• 11-year forecast
• EGFR NSCLC Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (by geography)
• EGFR NSCLC Treatment Addressable Market (TAM)
• EGFR NSCLC Competitive Landscape
• EGFR NSCLC Major Companies Insights
• EGFR NSCLC Price Trends and Analogue Assessment
• EGFR NSCLC Therapies Drug Adoption/Uptake
• EGFR NSCLC Therapies Peak Patient Share Analysis

Report Assessment

• EGFR NSCLC Current Treatment Practices
• EGFR NSCLC Unmet Needs
• EGFR NSCLC Clinical Development Analysis
• EGFR NSCLC Emerging Drugs Product Profiles
• EGFR NSCLC Market Attractiveness
• EGFR NSCLC Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the EGFR NSCLC market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of EGFR NSCLC?
• What impact will patent expiry have on the EGFR therapy market?
• What are the disease risks, burdens, and unmet needs of EGFR NSCLC? What will be the growth opportunities across the 7MM concerning the patient population with EGFR NSCLC?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of EGFR NSCLC? What are the current guidelines for treating EGFR NSCLC in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the EGFR NSCLC market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of EGFR-NSCLC

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences and Meetings
• 4.3. Key Transactions and Collaborations
• 4.4. News Flow

5. Epidemiology and Market Forecast Methodology

6. EGFR-NSCLC Market Overview at a Glance

• 6.1. Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])
• 6.2. Market Share (%) Distribution of EGFR-NSCLC by Line of Therapy (LoT) in 2025 in the 7MM
• 6.3. Market Share (%) Distribution of EGFR-NSCLC by Line of Therapy (LoT) in 2036 in the 7MM

7. Disease Background and Overview

• 7.1. Introduction
• 7.2. Structure and Mechanism of EGFR
• 7.3. Types of EGFR Mutation in NSCLC
• 7.4. Risk Factors Associated With EGFR-mutated NSCLC
• 7.5. Diagnosis
  • 7.5.1. Biomarker Testing for EGFR Mutation
  • 7.5.2. Diagnosis Algorithm of EGFR
  • 7.5.3. Diagnosis Guidelines
• 7.6. Treatment
  • 7.6.1. Current Treatment
  • 7.6.2. Treatment Algorithm
  • 7.6.3. Treatment Guidelines

8. Epidemiology and Patient Population

• 8.1. Key Findings
• 8.2. Assumptions and Rationale
• 8.3. Total Incident Cases of EGFR-NSCLC in the 7MM
• 8.4. The United States
  • 8.4.1. Total Incident Cases of NSCLC in the United States
  • 8.4.2. Gender-specific Incident Cases of NSCLC in the United States
  • 8.4.3. Age-specific Incident Cases of NSCLC in the United States
  • 8.4.4. Total Incident Cases of NSCLC by Histology in the United States
  • 8.4.5. Total Incident Cases of NSCLC by Stage in the United States
  • 8.4.6. Total Incident Cases of EGFR-NSCLC in the United States
  • 8.4.7. Line-wise Treated Cases of EGFR-NSCLC in the United States
• 8.5. EU4 and the UK
  • 8.5.1. Total Incident Cases of NSCLC in EU4 and the UK
  • 8.5.2. Gender-specific Incident Cases of NSCLC in EU4 and the UK
  • 8.5.3. Age-specific Incident Cases of NSCLC in EU4 and the UK
  • 8.5.4. Total Incident Cases of NSCLC by Histology in EU4 and the UK
  • 8.5.5. Total Incident Cases of NSCLC by Stage in EU4 and the UK
  • 8.5.6. Total Incident Cases of EGFR-NSCLC in EU4 and the UK
  • 8.5.7. Line-wise Treated Cases of EGFR-NSCLC in EU4 and the UK
• 8.6. Japan
  • 8.6.1. Total Incident Cases of NSCLC in Japan
  • 8.6.2. Gender-specific Incident Cases of NSCLC in Japan
  • 8.6.3. Age-specific Incident Cases of NSCLC in Japan
  • 8.6.4. Total Incident Cases of NSCLC by Histology in Japan
  • 8.6.5. Total Incident Cases of NSCLC by Stage in Japan
  • 8.6.6. Total Incident Cases of EGFR-NSCLC in Japan
  • 8.6.7. Line-wise Treated Cases of EGFR-NSCLC in Japan

9. Patient Journey

10. Key Endpoints

11. Marketed Therapies

• 11.1. Key Cross Competition of Marketed Therapies
• 11.2. AUMSEQA (Aumolertinib): Jiangsu Hansoh Pharmaceutical
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activity
  • 11.2.4. Summary of Pivotal Clinical Trial
  • 11.2.5. Analyst View
• 11.3. VIZIMPRO (Dacomitinib): Pfizer
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Developmental Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Clinical Development
  • 11.3.6. Safety and Efficacy
  • 11.3.7. Analyst Views
• 11.4. GILOTRIF/GIOTRIF (Afatinib maleate): Boehringer Ingelheim
  • 11.4.1. Product Description
  • 11.4.2. Regulatory Milestones
  • 11.4.3. Other Developmental Activities
  • 11.4.4. Summary of Pivotal Trials
  • 11.4.5. Safety and Efficacy
  • 11.4.6. Analyst Views
• 11.5. TAGRISSO (Osimertinib): AstraZeneca
  • 11.5.1. Product Description
  • 11.5.2. Regulatory Milestones
  • 11.5.3. Other Developmental Activities
  • 11.5.4. Summary of Pivotal Trials
  • 11.5.5. Clinical Development
  • 11.5.6. Safety and Efficacy
  • 11.5.7. Analyst Views
• 11.6. PORTRAZZA (Necitumumab): Eli Lilly and Company
  • 11.6.1. Product Description
  • 11.6.2. Regulatory Milestones
  • 11.6.3. Other Developmental Activities
  • 11.6.4. Summary of Pivotal Trials
  • 11.6.5. Safety and Efficacy
  • 11.6.6. Analyst Views
• 11.7. RYBREVANT (Amivantamab) +- LAZCLUZE (Lazertinib): Johnson & Johnson Innovative Medicine/Yuhan Corporation
  • 11.7.1. Product Description
  • 11.7.2. Regulatory Milestones
  • 11.7.3. Other Developmental Activities
  • 11.7.4. Summary of Pivotal Trials
  • 11.7.5. Clinical Development
  • 11.7.6. Safety and Efficacy
  • 11.7.7. Analyst Views
• 11.8. ZEGFROVY (Sunvozertinib) : Dizal Pharmaceutical
  • 11.8.1. Product Description
  • 11.8.2. Regulatory Milestones
  • 11.8.3. Other Developmental Activities
  • 11.8.4. Summary of Pivotal Trials
  • 11.8.5. Clinical Development
  • 11.8.6. Safety and Efficacy
  • 11.8.7. Analyst Views
• 11.9. DATROWAY (Datopotamab Deruxtecan): Daiichi Sankyo/AstraZeneca
  • 11.9.1. Product Description
  • 11.9.2. Regulatory Milestones
  • 11.9.3. Other Developmental Activities
  • 11.9.4. Summary of Pivotal Trials
  • 11.9.5. Clinical Development
  • 11.9.6. Safety and Efficacy
  • 11.9.7. Analyst Views

12. Emerging drugs

• 12.1. Key Cross Competition of Emerging Therapies
• 12.2. Ivonescimab (AK112): Akeso Bio and Summit Therapeutics
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activity
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst Views
• 12.3. Firmonertinib: ArriVent BioPharma and Shanghai Allist Pharmaceuticals
  • 12.3.1. Product Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
  • 12.3.4. Safety and Efficacy
  • 12.3.5. Analyst Views
• 12.4. Sacituzumab Tirumotecan (MK-2870): Merck and Kelun-Biotech
  • 12.4.1. Product Description
  • 12.4.2. Other Developmental Activities
  • 12.4.3. Clinical Development
  • 12.4.4. Safety and Efficacy
  • 12.4.5. Analyst Views
• 12.5. Iza-bren (izalontamab brengitecan): SystImmune and Bristol Myers Squibb
  • 12.5.1. Product Description
  • 12.5.2. Other Developmental Activities
  • 12.5.3. Clinical Development
  • 12.5.4. Safety and Efficacy
  • 12.5.5. Analyst Views
• 12.6. PF-08046054: Pfizer
  • 12.6.1. Product Description
  • 12.6.2. Other Developmental Activities
  • 12.6.3. Clinical Development
  • 12.6.4. Safety and Efficacy
  • 12.6.5. Analyst Views
• 12.7. Zipalertinib (CLN-081): Cullinan Therapeutics and Taiho Pharma
  • 12.7.1. Product Description
  • 12.7.2. Other Developmental Activities
  • 12.7.3. Clinical Development
  • 12.7.4. Safety and Efficacy
  • 12.7.5. Analyst Views
• 12.8. SYS6010: CSPC Pharmaceutical
  • 12.8.1. Product Description
  • 12.8.2. Other Developmental Activities
  • 12.8.3. Clinical Development
  • 12.8.4. Safety and Efficacy
  • 12.8.5. Analyst Views
• 12.9. Telisotuzumab adizutecan, Temab-A (ABBV-400): AbbVie
  • 12.9.1. Product Description
  • 12.9.2. Other Developmental Activities
  • 12.9.3. Clinical Development
  • 12.9.4. Safety and Efficacy
  • 12.9.5. Analyst Views
• 12.10. Sutetinib: Teligene
  • 12.10.1. Product Description
  • 12.10.2. Clinical Development
  • 12.10.3. Safety and Efficacy
  • 12.10.4. Analyst Views
• 12.11. LP-300: Lantern Pharma
  • 12.11.1. Product Description
  • 12.11.2. Other Developmental Activities
  • 12.11.3. Clinical Development
  • 12.11.4. Safety and Efficacy
  • 12.11.5. Analyst Views
• 12.12. DB-1310: DualityBio
  • 12.12.1. Product Description
  • 12.12.2. Other Developmental Activities
  • 12.12.3. Clinical Development
  • 12.12.4. Safety and Efficacy
  • 12.12.5. Analyst Views
• 12.13. JIN-A02: J INTS BIO
  • 12.13.1. Product Description
  • 12.13.2. Other Developmental Activities
  • 12.13.3. Clinical Development
  • 12.13.4. Safety and Efficacy
  • 12.13.5. Analyst Views
• 12.14. Pamvatamig (MCLA-129): Merus
  • 12.14.1. Product Description
  • 12.14.2. Other Developmental Activities
  • 12.14.3. Clinical Development
  • 12.14.4. Safety and Efficacy
  • 12.14.5. Analyst Views
• 12.15. Quaratusugene ozeplasmid (REQORSA): Genprex
  • 12.15.1. Product Description
  • 12.15.2. Other Developmental Activities
  • 12.15.3. Clinical Development
  • 12.15.4. Safety and Efficacy
  • 12.15.5. Analyst Views
• 12.16. Silevertinib (BDTX-1535): Black Diamond Therapeutics
  • 12.16.1. Product Description
  • 12.16.2. Other Developmental Activity
  • 12.16.3. Clinical Development
  • 12.16.4. Safety and Efficacy
  • 12.16.5. Analyst Views

13. EGFR-NSCLC: 7MM Market Analysis

• 13.1. Key Findings
• 13.2. The 7MM
  • 13.2.1. Total Market Size of EGFR-NSCLC by Country in the 7MM
  • 13.2.2. Market Size of EGFR NSCLC by Therapies in the 7MM
• 13.3. Market Outlook
• 13.4. Conjoint Analysis
• 13.5. Key Market Forecast Assumptions
  • 13.5.1. Cost Assumptions and Rebates
  • 13.5.2. Pricing Trends
  • 13.5.3. Analogue Assessment
  • 13.5.4. Launch Year and Therapy Uptakes
• 13.6. The United States
  • 13.6.1. Total Market Size of EGFR NSCLC in the United States
  • 13.6.2. Market Size of EGFR NSCLC by Therapies in the United States
• 13.7. EU4 and the UK
  • 13.7.1. Total Market Size of EGFR NSCLC in EU4 and the UK
  • 13.7.2. Market Size of EGFR NSCLC by Therapies in EU4 and the UK
• 13.8. Japan
  • 13.8.1. Total Market Size of EGFR NSCLC in Japan
  • 13.8.2. Market Size of EGFR NSCLC by Therapies in Japan

14. Unmet Needs

15. SWOT Analysis

16. KOL Views

17. Market Access and Reimbursement

• 17.1. The United States
• 17.2. In EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Market Access and Reimbursement of EGFR-NSCLC Therapies

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight